EQT’s €450 Million Acquisition of Life Sciences Partners

Debevoise & Plimpton, Vinge and Loyens & Loeff advised EQT in the transaction. Hannes Snellman has advised the sellers of Life Sciences Partners (LSP).

EQT AB announced the signing of an agreement to acquire LSP (Life Sciences Partners), a leading European life sciences venture capital firm with approximately EUR 2.2 billion of assets under management (AUM) and a team of 34 professionals. LSP will strengthen EQT’s position as one of the leading and most active private markets investors in the healthcare sector.

The upfront consideration of the transaction amounts to €450 million.

LSP, headquartered in Amsterdam, the Netherlands, is a venture capital firm that invests in innovative companies with strong scientific and clinical rationale across several life sciences strategies. The Company was founded in 1998 and today is one of Europe’s largest and most experienced life sciences investment firms. LSP employs 34 professionals across its offices in Amsterdam, Munich, and Boston.

EQT is a purpose-driven global investment organization focused on active ownership strategies. With a Nordic heritage and a global mindset, EQT has a track record of almost three decades of delivering consistent and attractive returns across multiple geographies, sectors and strategies. 

The Debevoise team advising EQT was led by partners Matthew Dickman (Picture) and Patricia Volhard, and included international counsel John Young, and associates Nicola Bruton and Eric Olmesdahl.

Loyens & Loeff advised EQT with a team led by Antoinette van der Hauw and supported by Gearte Sijens, Anna van der Donk, Konstantina Antoniou, Freek Hilberdink, Erwin Bosma, Louis Lutz, Sandrine Lekkerkerker, Anne Remmers, Wendy Pronk, Sebastiaan Hooghiemstra, Sebastiaan Verkerk, Klaas Wiersma and Florentine Deur.

The Hannes Snellman’s core advisory team consisted of Mattias Friberg, Christoffer Saidac, and Khaled Talayhan.

Vinge’s team consisted of Christina Kokko, Karl Klackenberg and Milad Kamali (M&A), Sofie Bjärtun (Equity Capital Markets), Emma Johansson and Johan Wahlbom (Competition) and Emma Stuart-Beck and Caroline Krassén (Regulatory) and Ellinor Gyllenhammar (VDR Expert). 

Involved fees earner: Nicola Bruton – Debevoise & Plimpton; Matthew Dickman – Debevoise & Plimpton; Eric Olmesdahl – Debevoise & Plimpton; Patricia Volhard – Debevoise & Plimpton; John Young – Debevoise & Plimpton; Mattias Friberg – Hannes Snellman; Christoffer Saidac – Hannes Snellman; Khaled Talayhan – Hannes Snellman; Konstantina Antoniou – Loyens & Loeff; Erwin Bosma – Loyens & Loeff; Florentine Deur – Loyens & Loeff; Freek Hilberdink – Loyens & Loeff; Sebastiaan Hooghiemstra – Loyens & Loeff; Sandrine Lekkerkerker – Loyens & Loeff; Louis Lutz – Loyens & Loeff; Wendy Pronk – Loyens & Loeff; Anne Remmers – Loyens & Loeff; Gearte Sijens – Loyens & Loeff; Anna van der Donk – Loyens & Loeff; Antoinette van der Hauw – Loyens & Loeff; Sebastiaan Verkerk – Loyens & Loeff; Klaas Wiersma – Loyens & Loeff; Sofie Bjärtun – Vinge; Emma Johansson – Vinge; Milad Kamali – Vinge; Karl Klackenberg – Vinge; Christina Kokko – Vinge; Caroline Krassén – Vinge; Emma Stuart?Beck – Vinge; Johan Wahlbom – Vinge;

Law Firms: Debevoise & Plimpton; Hannes Snellman; Loyens & Loeff; Vinge;

Clients: EQT Corporation LP; Life Sciences Partners BV;